Biophytis (BPTSY) Competitors $1.33 -0.12 (-8.28%) As of 07/11/2025 Add Compare Share Share Competitors Stock AnalysisChartCompetitorsSEC FilingsShort InterestTrendsBuy This Stock BPTSY vs. AKAN, PTIX, CDT, SHPH, TNFA, SLRX, ONCT, BPTH, PTEIQ, and OGENShould you be buying Biophytis stock or one of its competitors? The main competitors of Biophytis include Akanda (AKAN), Atrinsic (PTIX), Conduit Pharmaceuticals (CDT), Shuttle Pharmaceuticals (SHPH), TNF Pharmaceuticals (TNFA), Salarius Pharmaceuticals (SLRX), Oncternal Therapeutics (ONCT), Bio-Path (BPTH), PolarityTE (PTEIQ), and Oragenics (OGEN). These companies are all part of the "pharmaceutical products" industry. Biophytis vs. Its Competitors Akanda Atrinsic Conduit Pharmaceuticals Shuttle Pharmaceuticals TNF Pharmaceuticals Salarius Pharmaceuticals Oncternal Therapeutics Bio-Path PolarityTE Oragenics Biophytis (NASDAQ:BPTSY) and Akanda (NASDAQ:AKAN) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, analyst recommendations, profitability, risk, valuation, earnings, institutional ownership and dividends. Which has preferable earnings and valuation, BPTSY or AKAN? Akanda has higher revenue and earnings than Biophytis. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBiophytisN/AN/A-$18.43MN/AN/AAkanda$840K2.20-$4.10MN/AN/A Which has more volatility and risk, BPTSY or AKAN? Biophytis has a beta of 0.81, suggesting that its stock price is 19% less volatile than the S&P 500. Comparatively, Akanda has a beta of 1.6, suggesting that its stock price is 60% more volatile than the S&P 500. Is BPTSY or AKAN more profitable? Company Net Margins Return on Equity Return on Assets BiophytisN/A N/A N/A Akanda N/A N/A N/A Does the media favor BPTSY or AKAN? In the previous week, Akanda had 2 more articles in the media than Biophytis. MarketBeat recorded 2 mentions for Akanda and 0 mentions for Biophytis. Akanda's average media sentiment score of 0.47 beat Biophytis' score of 0.00 indicating that Akanda is being referred to more favorably in the news media. Company Overall Sentiment Biophytis Neutral Akanda Neutral Do institutionals and insiders have more ownership in BPTSY or AKAN? 0.1% of Biophytis shares are owned by institutional investors. Comparatively, 1.0% of Akanda shares are owned by institutional investors. 3.7% of Biophytis shares are owned by insiders. Comparatively, 20.4% of Akanda shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth. SummaryAkanda beats Biophytis on 7 of the 7 factors compared between the two stocks. Get Biophytis News Delivered to You Automatically Sign up to receive the latest news and ratings for BPTSY and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding BPTSY and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart BPTSY vs. The Competition Export to ExcelMetricBiophytisPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$467K$724.83M$5.61B$9.29BDividend YieldN/A4.84%4.23%4.03%P/E RatioN/A1.1828.5419.58Price / SalesN/A25.52430.1194.56Price / CashN/A19.5636.0257.93Price / Book-0.086.918.145.54Net Income-$18.43M-$4.17M$3.24B$257.73M7 Day Performance-8.28%1.41%0.17%-0.08%1 Month PerformanceN/A1.34%5.95%8.09%1 Year Performance-80.18%7.45%26.22%13.02% Biophytis Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)BPTSYBiophytisN/A$1.33-8.3%N/AN/A$467KN/A0.0030Gap DownAKANAkanda0.7479 of 5 stars$1.42+10.9%N/A-71.6%$2.03M$836.66K0.00110PTIXAtrinsic0.5282 of 5 stars$3.43+1.2%N/A-66.9%$2.02MN/A-0.262CDTConduit Pharmaceuticals0.424 of 5 stars$2.46+1.7%N/A-99.4%$1.96MN/A0.003High Trading VolumeSHPHShuttle Pharmaceuticals0.4466 of 5 stars$4.25+5.2%N/AN/A$1.87MN/A-1.025TNFATNF PharmaceuticalsN/A$0.12+6.0%N/AN/A$1.70MN/A-0.026High Trading VolumeSLRXSalarius Pharmaceuticals0.418 of 5 stars$0.79-4.5%N/A-61.9%$1.68MN/A-0.1620Gap DownONCTOncternal TherapeuticsN/A$0.53flat$10.00+1,799.0%N/A$1.56M$790K-0.0530BPTHBio-Path0.817 of 5 stars$0.17+5.9%N/A-91.5%$1.41MN/A0.0010Gap UpPTEIQPolarityTEN/AN/AN/AN/A$1.24M$810K-0.0560Gap UpOGENOragenics0.0646 of 5 stars$1.50-2.6%N/A-96.2%$1.23MN/A-0.215Gap Down Related Companies and Tools Related Companies Akanda Alternatives Atrinsic Alternatives Conduit Pharmaceuticals Alternatives Shuttle Pharmaceuticals Alternatives TNF Pharmaceuticals Alternatives Salarius Pharmaceuticals Alternatives Oncternal Therapeutics Alternatives Bio-Path Alternatives PolarityTE Alternatives Oragenics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:BPTSY) was last updated on 7/16/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredCentral Banks Are Hoarding Gold – Should You?The AI boom isn’t just transforming technology—it’s redefining global power, increasing government debt, and u...Lear Capital | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Something big is brewing in Washington. According to my research, an executive order from President Trump c...Weiss Ratings | SponsoredAll New Social Security Numbers coming July 23?To All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredWhich Gold Miner Trades at 30% of NAV? The One Buffett WantsSome of the world’s best gold developers are trading at just 30% of NAV — like buying a dollar for 30 cents. ...Golden Portfolio | SponsoredWhy Elon is funding the “Quantum Power Grid”Elon knows the future isn’t about smarter AI — it’s about powering it. And this new technology is quietly b...True Market Insiders | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Biophytis S.A. Please log in to your account or sign up in order to add this asset to your watchlist. Share Biophytis With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
